Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications

Pugacheva E.L.

doi:https://doi.org/10.17116/jnevro202212205184

Pugacheva E.L.

Pavlov First Saint Petersburg State Medical University

Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications

Authors:

Pugacheva E.L.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5): 84‑89

DOI: 10.17116/jnevro202212205184

Read: 14398 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Pugacheva EL. Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):84‑89. (In Russ.)
https://doi.org/10.17116/jnevro202212205184

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

Complications of Diabetes mellitus (DM), depends on the severity of hypoxic tissue damage. Amelioration of hypoxic injury may improve current therapy approaches and enhance the quality of life in patient’s cohort suffered from DM.

MATERIAL AND METHODS

30 pts which DM were enrolled into the study. Mexidol forte, was given IV 500 mg/day for 14 days, follow up with oral administration 250 TID. Clinical impression, neuropsychological scales and biochemical blood tests were recorded.

RESULTS

Mexidol administration improved cognitive functions, decreased the level of asthenia, depressia, improved sleep disturbances, and normalized biochemical landscape.

CONCLUSIONS

Mexidol administration for the period 75 days may serve as important therapeutic supplementation and considered as adjunctive therapy in the treatment of patients with DM.

Keywords:

Diabetes mellitus

hypoxia

oxidative stress

antioxidants

neurotransmitters

antihypoxive medications

Mexidol

Authors:

Pugacheva E.L.

Pavlov First Saint Petersburg State Medical University

Received:

13.01.2022

Accepted:

01.02.2022

Close metadata

References:

Goldstein LB. Lipids in high-risk patients presenting with ischemic stroke or transient ischemic attack. Stroke. 2014;45(11):3180-3181. https://doi.org/10.1161/strokeaha.114.007436
Tuttolomondo A. Relationship between diabetes and ischemic stroke: analysis of diabetes-related risk factors for stroke and of specific patterns of stroke associated with diabetes mellitus. J Diabetes Metab. 2015;06(05):544-551. https://doi.org/10.4172/2155-6156.1000544
Dedov II, Shestakova MV, Vikulova OK. State Register of Diabetes Mellitus in the Russian Federation: Status 2014 and Development Prospects. Diabetes Mellitus. 2015;18(3):5-23. (In Russ.). https://doi.org/10.14341/DM201535-22
Howangyin KY, Silvestre J-S. diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arteriosclerosis Thrombosis Vasc Biol. 2014;34(6):1126-1135. https://doi.org/10.1161/atvbaha.114.303090
Tanashyan MM, Lagoda OV, Antonova KV, Raskurazhev AA. The main pathogenetic mechanisms of development of vascular pathology of the brain in atherosclerosis and metabolic syndrome: search for ways of correction. Clinical Neurology. 2016;10(2):5-9. (In Russ.).
Tanashyan MM, Lagoda OV, Antonova KV. Vascular diseases of the brain: prospects for pathogenetic metabolic hemangiocorrection. J Neur Psychiatry n.a. S.S. Korsakov. 2015;115(9):170-175. (In Russ.). https://doi.org/10.17116/jnevro20151159170-75
Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases on the background of metabolic syndrome: new approaches to treatment. J Neur Psychiatry n.a. S.S. Korsakov. 2012;112(11):21-26. (In Russ.).
Chu X, Kirgizova OY. Metabolic syndrome: some results and prospects for solving the problem. Acta Biomedica Scientifica. 2016;1(5):187-194. (In Russ.). https://doi.org/10.12737/23422
Skormets AA, Afanasyev VV, Skormets AP, Skomolets TA. Vascular diseases of the spinal cord. SPb.: Polytechnic; 2019;255-259. (In Russ.).
Gomazkov OA. Aging of the brain and neurotrophic therapy. M.: IKAR; 2011;178. (In Russ.).
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Torshin IYu, Gromova OA, Sardaryan IS, Fedotova LE. A comparative chemoreactome analysis of mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(1-2):75-83. (In Russ.). https://doi.org/10.17116/jnevro20171171275-84
Voronina TA. The role of hypoxia in the development of stroke and convulsions. Antihypoxants. Reviews of Clinical Pharmacology and Drug Therapy. 2016;14(1):63-70. (In Russ.). https://doi.org/10.17816/RCF14163-70
Voronina TA, Kapitsa IG, Ivanova EA. A comparative study of the effects of Mexidol and Mildronate on physical performance in an experiment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(4):70-73. (In Russ.). https://doi.org/10.17116/jnevro20171174171-74
Voronina TA. The role of oxidative stress and antioxidants in maladaptation of various genesis. Pharmacy and Pharmacology. 2015;3(5):8-17. (In Russ.). https://doi.org/10.19163/2307-9266-2015-3-5s
Gromova OA, Torshin IYu, Stakhovskaya LV, et al. Experience of mexidol in neurological practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10-1):94-104. (In Russ.). https://doi.org/10.17116/jnevro201811810197
Shchulkin AV. Modern ideas about the antihypoxic and antioxidant effects of mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
Kirova YuI, Shakova FM, Germanova EL, et al. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(1):62-69. (In Russ.). https://doi.org/10.17116/jnevro202012001162
Afanasyev VV, Barantsevich ER, Vishnevetskaya TP. ABC of neurocytoprotection. SPb.: Strela; 2016;279. (In Russ.).
Shchepankevich LA, Nikolaev YuA, Dolgova NA. Optimization of hypolipidemic therapy in patients with ischemic stroke and diabetes mellitus Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116(2):42-45. (In Russ.). https://doi.org/10.17116/jnevro20161162142-45
Mester NV. Influence of 3-oxypyridine derivatives on cognitive functions and affective status of patients with diabetes mellitus: Dis. ... kand. med. nauk. Chelyabinsk State Medical Academy. Chelyabinsk. 2007. (In Russ.).
Afanasyev VV, Pugacheva EL, Barantsevich ER, et al. Effectiveness of neurocytoprotectors of metabolic and mediator groups and their combinations in asthenic syndrome. Effective Pharmacotherapy. 2020;16(31):60-66. (In Russ.).
Belova AN, Shchepetova ON. Scales, tests and questionnaires in medical rehabilitation: a guide for doctors and scientists. M.: AST; 2002;440. (In Russ.).